Table II.

Antihypertensive Therapy and Blood Pressure During Follow‐Up (SBP/DBP)

	Blood Pressure Goal Intervention		Drug Intervention
	Lower	Usual	Ramipril	Amlodipine	Metoprolol
MAP, mean (SE), mm Hg†	95(8)	104 (7)	100 (9)	99 (8)	100 (9)
SBP, mean (SE), mm Hg†	128 (12)	141 (12)	135 (14)	133 (12)	135 (13)
DBP, mean (SE), mm Hg†	78 (8)	85 (7)	82 (9)	81 (8)	81 (9)
Visits with MAP in goal, %†	51.6	39.2	44.1	48.9	44.7
Visits with MAP of <107 mm Hg†	81.3	64.3	71.5	76.5	72.0
Visits with SBP/DBP of <140/90, %†	68.6	35.5	51.2	54.9	50.8
Visits with SBP/DBP of <125/75, %†	24.7	6.2	16.2	14.4	14.9
Visits with assigned primary drug, %‡	81.7	80.1	76.8	83.4	83.6
Visits with high dose, %‡	62.8	45.0	53.5	54.6	53.6
Visits with crossover to one of other two classes, %‡	9.3	8.1	10.9	6.4	7.6
Total no. of drug classes, mean (SE)‡	3.04 (1.14)	2.39 (1.18)	2.66 (1.23)	2.65 (1.24)	2.79 (1.15)
Visits with level 2 (furosemide), %‡	82.2	66.6	74.0	70.8	76.4
Visits with level 3 (doxazosin), %‡	55.2	34.4	42.0	46.3	46.6
Visits with level 4 (clonidine), %‡	40.5	27.3	34.4	34.4	33.1
Visits with level 5 (minoxidil), %‡	34.9	22.7	27.5	24.1	32.3
Protocol visits held, %	90.3	87.5	88.0	88.7	89.8
MAP=mean arterial pressure; SBP/DBP=systolic/diastolic blood pressure; †blood pressure summaries include visits after 3 months and exclude glomerular filtration rate visits; ‡Medication summaries include all visits starting at month 1 and are censored as of September 22, 2000, for the calcium channel blocker (amlodipine) group only.